Ropinirole in Gilles de la Tourette syndrome

Marietta H. Anca; Nir Giladi; Amos D. Korczyn

doi:10.1212/01.WNL.0000123111.00324.BF

Ropinirole in Gilles de la Tourette syndrome

Marietta H. Anca, Nir Giladi, Amos D. Korczyn^*

^*Corresponding author for this work

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.

Original language	English
Pages (from-to)	1626-1627
Number of pages	2
Journal	Neurology
Volume	62
Issue number	9
DOIs	https://doi.org/10.1212/01.WNL.0000123111.00324.BF
State	Published - 11 May 2004

Access to Document

10.1212/01.WNL.0000123111.00324.BF

Cite this

@article{fb431749be374881aaca5c29bbc1bb5d,

title = "Ropinirole in Gilles de la Tourette syndrome",

abstract = "The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.",

author = "Anca, {Marietta H.} and Nir Giladi and Korczyn, {Amos D.}",

year = "2004",

month = may,

day = "11",

doi = "10.1212/01.WNL.0000123111.00324.BF",

language = "אנגלית",

volume = "62",

pages = "1626--1627",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

TY - JOUR

T1 - Ropinirole in Gilles de la Tourette syndrome

AU - Anca, Marietta H.

AU - Giladi, Nir

AU - Korczyn, Amos D.

PY - 2004/5/11

Y1 - 2004/5/11

N2 - The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.

AB - The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study, and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary.

UR - http://www.scopus.com/inward/record.url?scp=2342663132&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000123111.00324.BF

DO - 10.1212/01.WNL.0000123111.00324.BF

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:2342663132

SN - 0028-3878

VL - 62

SP - 1626

EP - 1627

JO - Neurology

JF - Neurology

IS - 9

ER -

Ropinirole in Gilles de la Tourette syndrome

Abstract

Access to Document

Other files and links

Fingerprint

Cite this